# Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

> **NCT01877694** · PHASE2 · COMPLETED · sponsor: **NovaBay Pharmaceuticals, Inc.** · enrollment: 217 (actual)

## Conditions studied

- Bacterial Conjunctivitis

## Interventions

- **DRUG:** Auriclosene Solution 0.3%
- **DRUG:** Auriclosene Vehicle

## Key facts

- **NCT ID:** NCT01877694
- **Lead sponsor:** NovaBay Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-12
- **Final completion:** 2015-01
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2015-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01877694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01877694, "Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01877694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*